Анализ акций TLPH
TL
Нет оценки
Количественный анализ Eyestock не покрывает акции Talphera Inc.
Рейтинг
Для оценки качества бизнеса компании мы собрали все финансовые данные из отчетов и представили их в виде одного числа - рейтинга компании. Значение рейтинга 100 является пороговым для определения актуальной инвестиционной идеи.
Низкий рейтинг
Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 15 full-time employees. The company went IPO on 2011-02-11. The firm is focused on the development and commercialization of therapies for use in medically supervised settings. The firm's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The firm is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.